Nektar Therapeutics (NKTR) is conducting a trial that will test NKTR-255 in patients with relapsed-refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), explains biotech specialist John McCamant, editor of The Medical Technology Stock Letter.